As the novel coronavirus spreads across China, healthcare and medicine production is being progressively affected due to pharmaceutical manufacturing units coming under lockdown. India being a major importer of Chinese pharmaceutical products is now in a strenuous position to handle its supply chain of basic medicine products. As Indian pharmas wait for China to commence production, bodies like the Indian Drug Manufacturers' Association (IDMA) and the government have to make sure that the country does not face a shortage of medicines.
The repercussions of the novel coronavirus outbreak, which has now been named Coronavirus disease 2019 (COVID-2019) by the WHO are also being felt on the economic spectrum. As businesses around the globe await the commencement of production in China, a major concern for the healthcare sector, especially in India, is the unfavourable impact the outbreak…
